AB0268 Vitamin D receptor polymorphisms in early inflammatory arthritis are associated with clinical outcomes and IGM responses to common pathogens but not baseline disease activity. (23rd January 2014)

• Record Type: Journal Article
• Authors: Hitchon, C.; Larcombe, L.; Newkirk, M.; Mookherjee, N.; Peschken, C.; El-Gabalawy, H.
• Is Part Of: Annals of the rheumatic diseases. Volume 71(2012)Supplement 3
• Page Start: 653
• Page End: 653
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2012-eular.268
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Vitamin D (VitD) exerts immunoregulatory activities of potential importance to rheumatoid arthritis and acts by binding to nuclear vitamin D receptors (VitDr) and regulating gene expression. VitDr single nucleotide polymorphisms (snps) have been variably linked to disease activity in rheumatoid arthritis and to chronic infections which have also been linked to inflammation. Objectives: To assess the association of VitDr snps (Fokl, Bsm1, Apa1 and Taq1) with clinical disease activity at baseline and one year, and antibody responses to common pathogens in patients with inflammatory arthritis of less than 1 year symptom duration. Methods: VitDr snps were assessed by polymerase chain reaction sequencing and analyzed using genotypic (DD vs Dd vs dd), dominant (DD, Dd vs dd), and recessive (DD vs Dd, dd) models. At first visit before DMARD treatment, serum VitD levels, serum antibody titers to E Coli and Proteus mirabilis (IgG, IgA and IgM), and CCP2 antibodies were measured by ELISA. Smoking was assessed by self report and cotinine levels. Associations of VitDr snps with clinical disease activity at baseline and one year and achievement of remission (DAS28CRP (3variable) <2.6) or EULAR treatment response at one year were tested. Results: Subjects (n=228) were predominantly female (72%) and Caucasian (87%), with mean age at first visit of 47.8 years (range 17-82, SD 14), a mean DAS28CRP (3variable) 3.91 (1.35), (31% low, 50% moderate 19% high disease activity) and were RF (54%) or CCP2 positive (44%). Of the 154 subjects with one year follow-up data, 67% achieved low disease activity. The VitDr minor allele frequencies were Fokl 0.42, Bsm1 0.55, Apa1 0.51, and Taq1 0.37. There was an association between Taq1 dominant alleles (TT, Tt) and at least one copy of shared epitope allele (p=0.01). No robust associations were seen between VitDr snps and gender, age at first visit, RF or CCP2 or baseline disease activity. Fokl dominant alleles (FF, Ff) had higher baseline anti-E.Coli IgM titers (0.51 vs 0.34 units p<0.01) and anti-proteus IgM titers (1.34 vs 1.18 units p<0.05), and at one year had higher DAS28CRP (3 variable) scores (2.92 vs 2.44 p<0.05) and were less likely to achieve remission (41% vs 73% p<0.01). In multivariate models including CCP2, rheumatoid factor, shared epitope, smoking (ever), and baseline serum VitD, only lower baseline DAS28CRP (3 variable) (p=0.001), Fokl recessive alleles (ff) (p<0.01) and higher IgM E.Coli titers (p<0.05) predicted remission at one year. Conclusions: Vitamin D receptor snps, especially Fokl, associate with IgM immune responses to common pathogens and associate with disease outcome in EIA but do not associate with baseline disease activity. Vitamin D receptor mediated regulation of immune responses may be important for the predisposition to inflammatory arthritis by breaking immune tolerance. Disclosure of Interest: None Declared